<DOC>
	<DOCNO>NCT02439125</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability efficacy eltoprazine treat levodopa-induced dyskinesia patient Parkinson 's disease</brief_summary>
	<brief_title>A Study Efficacy Safety Eltoprazine HCl Treating Levodopa-induced Dyskinesia Parkinson 's Disease Patients</brief_title>
	<detailed_description>A double-blind , placebo-controlled , crossover , dose-range finding study patient Parkinson 's disease levodopa-induced dyskinesia . The study examine effect three different dos eltoprazine HCl , compare placebo , severity dyskinesia , parkinsonian symptom , patient function , safety tolerability , use Parkinson 's disease rating scale , patient diary physiological measurement abnormal movement mean motion sensor .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Eltoprazine</mesh_term>
	<criteria>outpatient idiopathic PD stable dose antiparkinsonian medication least four week Screening Visit daily levodopa dose â‰¥300 mg per day divide least three dos treat levodopa least three year prior study entry moderate severely disable levodopainduced dyskinesia least three month prior study entry dyskinesia , average , &gt; 25 % wake day inability use motion sensor electronic diary correctly surgical treatment PD , e.g . Deep Brain Stimulation , within last six month plan study unstable coexist psychiatric disease include psychosis , depression cognitive impairment Mini Mental State Examination score &lt; 24 moderate severe renal , severe hepatic , impairment treatment selective serotonin reuptake inhibitor ( SSRI ) combine serotoninnorepinephrine reuptake inhibitor ( SNRI ) , tryptizol , citalopram , escitalopram , sertraline , mianserin , mirtazapin , paroxetin , venlafaxine St John 's Wort , within four week prior Screening Visit treatment medication potential druginteractions ( MAOA inhibitor , apomorphine , aripiprazol , carbamazepine , clozapine , phenytoin , tramadol , quetiapine , varfaine , valproic acid ) . Patients take amantadine comprise 25 % study population current history clinically significant uncontrolled medical condition may affect safety patient preclude adequate participation study pregnant breastfeeding receive investigational medicinal product within 30 day Screening</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>levodopa</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>parkinson disease</keyword>
	<keyword>PD</keyword>
</DOC>